AstraZeneca cleared over Brilinta trial

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (NYSE:AZN) says that the U.S. government has closed a probe that investigated a major clinical trial used to win marketing approval for the company's new heart drug Brilinta.

Following the DOJ's investigation into the study last October, doubts have ensued over the medicine's future success.

AstraZeneca argues that Brilinta can bring in $3.5B in annual sales, although until now the drug has not made any record performance.